Cargando…

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

PURPOSE: Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role of tocilizumab in combination with other treatments is uncertain. Here we evaluated whether tocilizumab plus remdesivir provides greater benefit than remdesivir alone in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosas, Ivan O., Diaz, George, Gottlieb, Robert L., Lobo, Suzana M., Robinson, Philip, Hunter, Bradley D., Cavalcante, Adilson W., Overcash, J. Scott, Hanania, Nicola A., Skarbnik, Alan, Garcia-Diaz, Julia, Gordeev, Ivan, Carratalà, Jordi, Gordon, Oliver, Graham, Emily, Lewin-Koh, Nicholas, Tsai, Larry, Tuckwell, Katie, Cao, Huyen, Brainard, Diana, Olsson, Julie K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490137/ https://www.ncbi.nlm.nih.gov/pubmed/34609549 http://dx.doi.org/10.1007/s00134-021-06507-x

Ejemplares similares

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Remdesivir/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

Remdesivir/tocilizumab: Drug ineffective and off-label use: 2 case reports
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy and off label use: case report
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Off-label use and lack of efficacy: case report
Publicado: (2022)

Remdesivir/tocilizumab: Rebound of HCV viral load and loss of anti-HBs: case report
Publicado: (2021)

The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

Hydroxychloroquine/remdesivir/tocilizumab: Increase in corrected QT interval and off-label use: case report
Publicado: (2020)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2
por: Rosati, Michael, et al.
Publicado: (2021)

Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia
por: Judge, Ramzan, et al.
Publicado: (2022)

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
por: Goldman, Jason D., et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation
por: Castle, Ryan D, et al.
Publicado: (2021)

551. Remdesivir and Tocilizumab for the Treatment of Severe COVID-19 in a Community Hospital: A Retrospective Cohort Study
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial
por: Mohiuddin Chowdhury, Abu Taiub Mohammed, et al.
Publicado: (2022)

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome
por: Ali, Sabahat, et al.
Publicado: (2021)

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
por: Tom, Jennifer, et al.
Publicado: (2021)

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
por: Rosas, Ivan O., et al.
Publicado: (2022)

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19
por: Shivram, Haridha, et al.
Publicado: (2023)

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
por: Strand, Vibeke, et al.
Publicado: (2017)

534. The Use of Tocilizumab and Remdesivir in SARS- CoV-2 Patients in El Paso Texas: A Longitudinal Comparative Observational Study
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution
por: Ichiyama, Takashi, et al.
Publicado: (2022)

Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center
por: Mohanty, Bijaya, et al.
Publicado: (2021)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0f19uuhsplf8ojm2snqb6h3ao